Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells
Wang, ZhiweiNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationZhou, Xiuxia, Jingna Su, Shaoyan Feng, Lixia Wang, Xuyuan Yin, Jingzhe Yan, and Zhiwei Wang. 2016. “Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.” Oncotarget 7 (48): 79076-79088. doi:10.18632/oncotarget.12596. http://dx.doi.org/10.18632/oncotarget.12596.
AbstractPancreatic cancer (PC) is one of the most aggressive human malignancies worldwide and is the fourth leading cause of cancer-related deaths. Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant. Certain studies have demonstrated that curcumin exerts its anti-tumor function in a variety of human cancers including PC, via targeting multiple therapeutically important cancer signaling pathways. However, the detailed molecular mechanisms are not fully understood. Two transcriptional co-activators, YAP (Yes-associated protein) and its close paralog TAZ (transcriptional coactivator with PDZ-binding motif) exert oncogenic activities in various cancers. Therefore, in this study we aimed to determine the molecular basis of curcumin-induced cell proliferation inhibition in PC cells. First, we detected the anti-tumor effects of curcumin on PC cell lines using CTG assay, Flow cytometry, clonogenic assay, wound healing assay and Transwell invasion assay. We found that curcumin significantly suppressed cell growth, weakened clonogenic potential, inhibited migration and invasion, and induced apoptosis and cell cycle arrest in PC cells. We further measured that overexpression of YAP enhanced cell proliferation and abrogated the cytotoxic effects of curcumin on PC cells. Moreover, we found that curcumin markedly down-regulated YAP and TAZ expression and subsequently suppressed Notch-1 expression. Collectively, these findings suggest that pharmacological inhibition of YAP and TAZ activity may be a promising anticancer strategy for the treatment of PC patients.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32071939
- HMS Scholarly Articles